Research Article
Male Accessory Gland Infection: Relevance of Serum Total Testosterone Levels
Table 3
Differences between groups divided into sextiles according to the values of TT.
| | | Group 1
(TT ≤ 2.7)
(n = 34) | Group 2
(TT > 2.7 and ≤3.6)
(n = 33) | Group 3
(TT > 3.6 and ≤4.4)
(n = 37) | Group 4
(TT > 4.4 and ≤5.3)
(n = 30) | Group 5
(TT > 5.3 and ≤6.6)
(n = 36) | Group 6
(TT > 6.6)
(n = 30) |
| | Age, median (IQR) | 40.0
(36.0–42.0) | 41.0
(33.5–42.0) | 38.0
(31.5–42.0) | 33.0
(30.0–40.5)* | 36.0
(28.0–40.0)* | 30.0
(26.0–39.0)* | | BMI, median (IQR) | 26.5
(23.0–30.25) | 26.0
(23.0–30.0) | 24.0
(23.0–28.0) | 24.5
(23.0–28.0) | 23.0
(23.0–25.75)* | 22.0
(22.0–23.5)* | | FSH, median (IQR) | 3.2
(3.0–3.42) | 3.0
(2.85–3.2) | 3.0
(2.8–3.1) | 3.05
(2.8–3.2) | 2.8
(2.35–3.0)* | 2.5
(2.2–2.9)* | | LH, median (IQR) | 6.5
(6.0–7.2) | 6.0
(4.7–6.1) | 4.5
(4.2–5.1)* | 4.2
(4.07–4.6)* | 4.2
(3.52–4.6)* | 3.8
(3.1–4.2)* | | Duration of symptoms, median (IQR) | 28.0
(15.0–21.0) | 16.0
(15.0–28.0) | 9.0
(7.0–12.0)* | 6.0
(5.0–8.0)* | 5.0
(4.0–6.0)* | 3.0
(2.0–4.0)* | | Testicular volume, median (IQR) | 8.0
(6.75–10.0) | 10.0
(8.5–12.0)* | 15.0
(14.0–17.0)* | 17.0
(15.0–18.0)* | 19.0
(17.2–21.0)* | 22.0
(20.0–23.0)* | | Microbial forms (%) | 4 (11.8) | 5 (15.2) | 8 (21.6) | 4 (13.3) | 3 (8.3) | 4 (13.3) | | P | 7 (7.9) | 9 (10.1) | 16 (18.0) | 16 (18.0) | 22 (24.7) | 19 (21.3)† | | PV | 12 (21.1) | 12 (21.1) | 10 (17.5) | 9 (15.8) | 9 (15.8) | 5 (8.8) | | PVE | 14 (26.9) | 12 (23.1) | 8 (15.4) | 8 (15.4) | 7 (13.5) | 3 (5.8)† | | UP | 5 (6.5) | 3 (3.9) | 13 (16.9) | 16 (20.8) | 20 (26.0) | 20 (26.0)† | | BP | 31 (27.0) | 27 (23.5) | 19 (26.5) | 14 (12.2) | 17 (14.8) | 7 (6.1)† | | UPV | 7 (17.5) | 7 (17.5) | 8 (20.0) | 8 (20.0) | 7 (17.5) | 3 (7.5) | | BPV | 6 (35.3) | 5 (29.4) | 2 (11.8) | 1 (5.9) | 2 (11.8) | 1 (5.9) | | UPVE | 4 (16.7) | 4 (16.7) | 3 (12.5) | 5 (20.8) | 7 (29.2) | 1 (4.2) | | BPVE | 10 (33.3) | 8 (26.7) | 5 (16.7) | 2 (6.7) | 4 (13.3) | 1 (3.3)† | | HCUF | 2 (3.0) | 3 (4.5) | 10 (15.2) | 14 (21.2) | 19 (18.8) | 18 (27.3)† | | FSUF | 22 (30.1) | 17 (23.3) | 12 (16.4) | 9 (12.3) | 10 (13.7) | 3 (4.1)† |
|
|
IQR: interquartile range; *P < 0.05 versus Group 1; †P < 0.05 at chi-square test.
UP: unilateral prostatitis; BP: bilateral prostatitis; UPV: unilateral prostatovesiculitis; BPV: bilateral prostatovesiculitis; UPVE: unilateral prostato-vesiculo-epididymitis; BPVE: bilateral prostato-vesiculo-epididymitis.
|
